Head-To-Head Review: Silverback Therapeutics (NASDAQ:SBTX) versus Evelo Biosciences (NASDAQ:EVLO)

Valuation and Earnings

This table compares Evelo Biosciences and Silverback Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53 million	($13.01)	N/A
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-3.47

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Evelo Biosciences has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Institutional and Insider Ownership

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Evelo Biosciences and Silverback Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Silverback Therapeutics	N/A	-29.62%	-28.20%

Summary

Silverback Therapeutics beats Evelo Biosciences on 5 of the 8 factors compared between the two stocks.

About Evelo Biosciences

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.